Some of the largest series of advanced NSCLC patients with PD-L1 ≥50% report an encouraging mOS from 20 months to 26.5 months with first-line, mainly pembrolizumab, immunotherapy (28–34). This evidence concerns the gene CD274 and non-small cell lung carcinoma.